“…The radiolabeled heterobivalent peptides described thus far are discussed in the following paragraphs and summarized in Table 1. Recently, not only the addressed target receptors broadened significantly, but also the potential application of the agents expanded from mainly PET imaging to PET and SPECT imaging as well as tumor therapy, entailing the use of different diagnostic ( 18 F, 64 Cu, 68 Ga, 86 Y, 99m Tc, and 111 In) as well as therapeutic ( 90 Y, 125 I, and 177 Lu) radionuclides ( Table 2). Although approaches to combine GRPR and PSMA binders to radiolabeled heterobivalent ligands emerged only in 2014, there were several agents already described in this group of heterobivalent peptidic agents, some of them showing high clinical potential.…”